KRESLADI

This brand name is authorized in United States.

Active ingredients

The drug KRESLADI contains one active pharmaceutical ingredient (API):

`1`	Marnetegragene autotemcel UNII `RD86XHH46N` - MARNETEGRAGENE AUTOTEMCEL
	Marnetegragene autotemcel adds functional copies of the ITGB2 gene into patients' hematopoietic stem cells (HSCs) through transduction of autologous CD34+ cells with LV-RP-201. After marnetegragene autotemcel infusion, transduced CD34+ HSCs engraft in the bone marrow and differentiate into various cell types, including leukocytes capable of expressing functional CD18 protein. Functional CD18 protein enables formation of the CD18/CD11a heterodimer (Leukocyte Function-Associated Antigen-1, LFA-1) which facilitates leukocyte adhesion to endothelial surfaces and extravasation to infectious and inflammatory sites.
	Read more about Marnetegragene autotemcel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KRESLADI Suspension for infusion	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	83537-034

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.